CLEOPATRA
E902899
CLEOPATRA is a clinical trial that evaluated the effectiveness and safety of combining pertuzumab with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CLEOPATRA canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074747 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CLEOPATRA Context triple: [CLEOPATRA trial, acronym, CLEOPATRA]
-
A.
Cleopatra
Cleopatra is a 1934 historical epic film starring Claudette Colbert as the Egyptian queen, renowned for its lavish production and influential cinematography.
-
B.
Cleopatra
Cleopatra was a daughter of the Powhatan chief Wahunsenacawh (Chief Powhatan) and a Native American woman of the Powhatan Confederacy in early 17th-century Virginia.
-
C.
Cleopatra VII
Cleopatra VII was the last active ruler of the Ptolemaic Kingdom of Egypt, renowned for her political acumen, relationships with Julius Caesar and Mark Antony, and her dramatic role in the final years of the Roman Republic.
-
D.
Cleopatra Alcyone
Cleopatra Alcyone is a figure from Greek mythology, known as the daughter of Meleager and Cleopatra and associated with the royal lineage of Calydon.
-
E.
Cleopatra III of Egypt
Cleopatra III of Egypt was a Ptolemaic queen and co-ruler of Hellenistic Egypt known for her turbulent reign marked by dynastic conflicts and shifting political alliances.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CLEOPATRA Target entity description: CLEOPATRA is a clinical trial that evaluated the effectiveness and safety of combining pertuzumab with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
-
A.
Cleopatra
Cleopatra is a 1934 historical epic film starring Claudette Colbert as the Egyptian queen, renowned for its lavish production and influential cinematography.
-
B.
Cleopatra
Cleopatra was a daughter of the Powhatan chief Wahunsenacawh (Chief Powhatan) and a Native American woman of the Powhatan Confederacy in early 17th-century Virginia.
-
C.
Cleopatra VII
Cleopatra VII was the last active ruler of the Ptolemaic Kingdom of Egypt, renowned for her political acumen, relationships with Julius Caesar and Mark Antony, and her dramatic role in the final years of the Roman Republic.
-
D.
Cleopatra Alcyone
Cleopatra Alcyone is a figure from Greek mythology, known as the daughter of Meleager and Cleopatra and associated with the royal lineage of Calydon.
-
E.
Cleopatra III of Egypt
Cleopatra III of Egypt was a Ptolemaic queen and co-ruler of Hellenistic Egypt known for her turbulent reign marked by dynastic conflicts and shifting political alliances.
- F. None of above. chosen
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III clinical trial ⓘ |
| acronymFor | CLinical Evaluation Of Pertuzumab And TRAstuzumab ⓘ |
| allocation | randomized allocation ⓘ |
| biomarkerStatus | HER2-positive ⓘ |
| cancerType | metastatic breast cancer ⓘ |
| chemotherapyAgent | docetaxel ⓘ |
| controlArmTreatment | trastuzumab plus docetaxel ⓘ |
| controlType | placebo control ⓘ |
| design |
double-blind
ⓘ
multicenter ⓘ placebo-controlled ⓘ randomized ⓘ |
| diseaseStage | metastatic ⓘ |
| drugClassEvaluated | HER2-targeted monoclonal antibodies ⓘ |
| evaluatedDrug |
docetaxel
ⓘ
pertuzumab ⓘ trastuzumab ⓘ
linked to:
Herceptin
|
| experimentalArmTreatment | pertuzumab plus trastuzumab plus docetaxel ⓘ |
| fullName | CLinical Evaluation Of Pertuzumab And TRAstuzumab ⓘ |
| geographicScope | international trial ⓘ |
| HER2StatusAssessment | immunohistochemistry and/or in situ hybridization ⓘ |
| impact | established dual HER2 blockade with pertuzumab and trastuzumab as standard of care in first-line metastatic setting ⓘ |
| indication | HER2-positive metastatic breast cancer ⓘ |
| ledTo | regulatory approval of pertuzumab for HER2-positive metastatic breast cancer ⓘ |
| masking | double-blind masking ⓘ |
| patientSex | predominantly female patients ⓘ |
| population | previously untreated HER2-positive metastatic breast cancer patients ⓘ |
| primaryEndpoint |
overall survival
ⓘ
progression-free survival ⓘ |
| publicationType | landmark trial in HER2-positive metastatic breast cancer ⓘ |
| safetyOutcome | acceptable safety profile for pertuzumab plus trastuzumab plus docetaxel ⓘ |
| showedBenefit |
improved overall survival with pertuzumab combination
ⓘ
improved progression-free survival with pertuzumab combination ⓘ |
| sponsor |
Genentech
ⓘ
Roche ⓘ |
| target |
human epidermal growth factor receptor 2
ⓘ
linked to:
ERBB2
|
| targetAbbreviation | HER2 ⓘ |
| therapyCategory | targeted therapy plus chemotherapy ⓘ |
| treatmentBackbone | taxane-based chemotherapy ⓘ |
| trialPhase | phase III ⓘ |
| trialType | interventional study ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: CLEOPATRA Description of subject: CLEOPATRA is a clinical trial that evaluated the effectiveness and safety of combining pertuzumab with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.